Abstracts tagged "Angiogenesis and endothelial cells"

Abstract Number: 3006 • 2014 ACR/ARHP Annual Meeting
Activation of the Thromboxane A2 Receptor By 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma
Pei-Suen Tsou¹, George Zakhem², Beatrix Balogh², M. Asif Amin³, Phillip Campbell⁴, Gautam Edhayan³, Ray A. Ohara³, Elena Schiopu³, Dinesh Khanna¹, Alisa E. Koch^2,5 and David A. Fox³, ¹University of Michigan Scleroderma Program, Ann Arbor, MI, ²University of Michigan Medical School, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Department of Veteran's Affairs and University of Michigan, Ann Arbor, MI
Background/Purpose: Scleroderma (SSc) is a complex disease characterized by inflammation, vasculopathy, and excessive deposition of extracellular matrix. Various studies have demonstrated a paradoxical increase in…
Abstract Number: 1966 • 2014 ACR/ARHP Annual Meeting
CTLA4-Ig (abatacept) Modulate in Vitro the ICAM1 and VEGFR-2 Expression in Human Endothelial Cells
Maurizio Cutolo¹, Paola Montagna², Stefano Soldano², Paola Contini³, Barbara Villaggio⁴, Alberto Sulli¹, Sabrina Paolino¹, Carmen Pizzorni¹, Bruno Seriolo¹, Giuseppe Zampogna², Marco A. Cimmino¹ and Renata Brizzolara², ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ³Division of Clinical Immunology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁴Research Laboratory of Nephrology, Department of Internal Medicine, University of Genova, Genova, Italy
Background/Purpose CTLA4-Ig (abatacept) is employed as biological agent in rheumatoid arthtritis (RA) treatment and interacts with the costimulatory molecule CD86 expressed by different cells involved…
Abstract Number: 928 • 2013 ACR/ARHP Annual Meeting
The Bioenergetic Role of HIF-1 and HIF-2 During Angiogenesis of Human Microvascular Endothelial Cells
Martin Hahne¹, Cindy Strehl¹, Manuela Jakstadt¹, Paula Hoff¹, Timo Gaber¹, Gerd Burmester² and Frank Buttgereit³, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Hypoxia is a feature of inflamed tissues. The transcription factors Hypoxia inducible factor (HIF)-1 and (HIF)-2 regulate the cellular and metabolic responses to reduced…
Abstract Number: 927 • 2013 ACR/ARHP Annual Meeting
The Role of HIF-1 and HIF-2 During Angiogenesis and Metabolic Adaptation of Human Microvascular Endothelial Cells Towards Hypoxia
Martin Hahne¹, Cindy Strehl¹, Manuela Jakstadt¹, Paula Hoff¹, Timo Gaber¹, Gerd Burmester² and Frank Buttgereit³, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Hypoxia is a feature of RA synovitis. In the present study, we focused on the two transcription factors Hypoxia inducible factor (HIF)-1 and (HIF)-2.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].